Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.35 |
| ▸ | EDNRB | P24530 | 2/20 | 0.35 |
| ▸ | EDNRA | P25101 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20807647 | 0.79 | NSD2 (0.45) | SMN1; SMN2LMNAHPGDMAPTKDM4E | |
| SCHEMBL3950722 | 0.79 | HTT (0.64) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL977122 | 0.79 | EDNRB (0.40) | SMN1; SMN2LMNAHPGDMAPTKDM4E | |
| SCHEMBL29401495 | 0.79 | EDNRB (0.40) | SMN1; SMN2LMNAHPGDMAPTKDM4E | |
| SCHEMBL22409314 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2LMNAHPGDMAPTKDM4E | |
| SCHEMBL22409253 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTKDM4EMEN1KMT2A | |
| SCHEMBL29405486 | 0.77 | EDNRB (0.41) | SMN1; SMN2LMNAHPGDMAPTKDM4E | |
| SCHEMBL2804042 | 0.77 | L3MBTL1 (0.47) | SMN1; SMN2LMNAHPGDMAPTKDM4E | |
| SCHEMBL22409170 | 0.77 | EDNRB (0.41) | SMN1; SMN2LMNAHPGDMAPTKDM4E | |
| SCHEMBL979667 | 0.76 | NOTUM (0.49) | SMN1; SMN2HPGDMAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220259198-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-114072390-A | RAD51 inhibitors | 赛泰尔治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3938358-A1 | RAD51 INHIBITORS | Cyteir Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2020186006-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020186006-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247988-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | SMN1; SMN2 245/4885LMNA 2555/4885HPGD 1959/4885 |
| US-20220259198-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | SMN1; SMN2 245/4885LMNA 2555/4885HPGD 1959/4885 |
| US-20200291014-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | SMN1; SMN2 245/4885LMNA 2555/4885HPGD 1959/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | SMN1; SMN2 245/4885LMNA 2555/4885HPGD 1959/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | SMN1; SMN2 245/4885LMNA 2555/4885HPGD 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.